### **HBV Combo Rapid Test Cassette** Package Insert Serum/Plasma

A rapid test for the qualitative detection of Hepatitis B Surface Antigen (HBsAg), Hepatitis B Surface Antibody (HBsAb), Hepatitis B Envelope Antigen (HBeAg), Hepatitis B Envelope Antibody (HBeAb), and Hepatitis Core Antibody (HBcAb) in serum or plasma. For professional in vitro diagnostic use only.

[INTENDED USE]
The HBV Combo Rapid Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of HBsAg, HBsAb, HBeAg, HBeAb and HBcAb in serum or plasma. [SUMMARY]

cancer and death. Chronic hepatitis B is the main cause of liver cancer and the tenth leading cause of death worldwide, with 400,000,000 people infected with the virus. Every year, one million people worldwide are expected to die from this infection. Chronic hepatitis B is a serious, debilitating illness that can cause cirrhosis of the liver.

Most people fight off the infection themselves, but approximately 5-10 percent of those infected with the virus become carriers, and an additional 5-10 percent of those infected each year will

progress to chronic liver disease, cirrhosis and possibly liver cancer.

The HBVCombo Rapid Test Cassette (Serum/Plasma) is a rapid test to qualitatively detect the presence of HBsAg, HBsAb, HBeAg, HBeAb and HBcAb in serum or plasma without the use of

### INCIPLE

The HBsAg and HBeAg tests are qualitative, two-site sandwich immunoassays for the detection of HBsAg or HBeAg in serum or plasma. The membrane is pre-coated with ant-HBsAg or anti-HBeAg antibodies on the test line region of the strip. During testing, the serum or plasma specimen reacts with the particle coated with anti-HBsAg or anti-HBeAg antibodies. 2The mixture migrates upward on the membrane chromatographically by capillary action to react with anti-HBsAg or anti-HBeAg antibodies on the membrane and generate action to reach with anti-HBsAg or anti-HBeAg antibodies on the membrane and generate action to reach with anti-HBsAg or anti-HBeAg antibodies on the membrane and generate actions in the test line region indicates a positive result, and the second of the while its absence indicates a negative result

serum or plasma. The membrane is pre-coated with HBsAg on the test line region of the strip. During testing, the serum or plasma specimen reacts with the particle coated with HBsAg. The mixture migrates upward on the membrane chromatographically by capillary action to react with HBsAg on the membrane and generate a colored line. The presence of this colored line in the test line region indicates a positive result, while its absence indicates a negative result. Hepatitis B surface Antibody (HBsAb) is also known as anti-Hepatitis B surface Antigen (anti-HBs). This test is a qualitative, lateral flow immunoassay for the detection of HBsAb in

## HBeAb and HBcAt

Hepatitis B envelope Antibody (HBeAb) is also known as anti-Hepatitis B envelope Antigen (anti-HBe), Hepatitis B core Antibody (HBeAb) is also known as anti-Hepatitis B core Antigen (anti-HBe). These tests are immunoassays based on the principle of competitive binding. During testing, the mixture migrates upward on the membrane chromatographically by capillary action. The membrane is pre-coated with HBeAg or HBcAg on the test line region of the strip. During testing, anti-HBe antibody or anti-HBe antibody, if present in the specimen, will compete the strip that the specimen of the strip that the specimen is pre-coated with HBeAg or HBcAg on the test line region of the strip.

with particle coated anti-HBe antibody or anti-HBc antibody for limited amount of HBeAg or HBeAg on the membrane, and no line will form in the test line region, indicating a positive result. A visible colored line will form in the test line region if there is no anti-HBe antibody or the antigen coated in the test line region anti-HBc antibody in the specimen because all the antibody coated particles will be captured by

To serve as a procedural control, a colored line will alw indicating that proper volume of specimen has been always appear in the control line region en added and membrane wicking has

### [REAGENTS]

The test cassette contains anti-HBsAg particles, HBsAg particles, anti-HBeAg particles, HBcAg particles respectively and anti-HBsAg, HBsAg, anti-HBeAg, Anti-HBcAg coated on the membrane respectively

## [PRECAUTIONS]

- Please read all the information in this package insert before performing the test.
  1. For professional in vitro diagnostic use only. Do not use after the expiration date.
  2. Do not eat, dnik or smoke in the area where the specimens or kits are handled.
  3. Hand all specimens as if they contain infectious agents. Observe established precautions microbiological hazards throughout testing and follow the standard procedures for
- proper disposal of specimens.

  4. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested

# **[STORAGE AND STABILITY]** can adversely affect results

Store as packaged at room temperature or refrigerated (2-30°C). The test cassette is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

[SPECIMEN COLLECTION AND PREPARATION]

The HBV Combo Rapid Test Cassette can be performed using either serum or plasma.
 Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear

- be stored at 2-8°C for up to 3 days. For long term storage, specimens should be kept below non-hemolyzed specimens.

  Testing should be performed immediately after specimen collection. Do specimens at room temperature for prolonged periods. Serum and plasma Do not leave may the
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and
- e If specimens are to be shipped, they should be packed in compliance with federal regulations covering the transportation of etiologic agents

# Materials provided

Materials required but not provided Dropper:

Package insert

Ca

Specimen collection containers Centrifuge · Timer

I DIRECTIONS FOR USE


Test cassettes [MATERIALS]

Remove the test cassette from the sealed foil pouch and use it as soon as possible. Best

results will be obtained if the assay is performed within one hour.

Place the test cassette on clean and level surface. Hold the dropper vertically and transfer 3 full drops of serum or plasma (approx.75u) to each sample well of the test cassette respectively, then start the timer. Avoid trapping air bubbles in the specimen well. See the

Wait for the red line to appear. The result should be read at 15 minutes. Do not interpret the results after 20 minutes.



# [INTERPRETATION OF RESULTS]

Warning: Do not interpret all 5 tests with the same criterion. Carefully follow the directions Please refer to the illustration above)

## HBsAg, HBsAb, HBeAc

POSITIVE: Two distinct colored lines appear. One colored line should be in the control region (C) and another colored line should be in the test region (T).

NOTE: The intensity of the color in the test line region (T) will vary depending on the concentration of HBsAg, HBsAb, HBeAg present in the specimen. Therefore, any shade of color in the test region (T) should be considered positive.

NEGATIVE: One colored line appears in the control region (C). No apparent colored line

appears in the test region (I), appear.insufficient specimen volume or incorrect procedural INVALID: Control line fails to appear.insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat techniques are the most likely reasons for control line failure. Review the procedural techniques are the most likely reasons for control line failure. ately and contact your local distributor

NEGATIVE:\* Two distinct colored lines appear. One colored line should be in the control region (0) and another colored line should be in the test region (1).

\*NOTE: The intensity of the color in the test line region (1) may vary. But it should be considered negative whenever there is even a faint pink line.

\*Positive: One colored line appears in the control region (C).No apparent colored line appears in the control region (C).

appears in the test region (T).

NVALID: Control line fails to appear insufficient specimen volume or incorrect procedural the test with a new test cassette. If the problem persists, discontinue using ues are the most likely reasons for control line failure. Review the procedure and repeat t with a new test cassette. If the problem persists, discontinue using the test ki and contact your local distributor

# **[QUALITY CONTROL]**

A procedural control is included in the test. A red line appearing in the control line region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural

negative controls be tested as good laboratory practice to confirm the test procedure and verity proper test performance standards are not supplied with this kit; however, it is recommended that positive and

The HBV Combo Rapid Test Cassette is for professional in vitro diagnostic use only. The
test should be used for the detection of HBsAg, HBsAg, HBsAg and HBcAb in
serum or plasma specimen. Neither the quantitative value nor the rate of HBsAg, HBsAb,
HBsAg, HBsAb, HBcAb concentration can be determined by this qualitative test.
 The HBV Combo Rapid Test Cassette will only indicate the presence of HBsAg, HBsAb,
HBsAg, HBsAb and HBsAb in the specimen and should not be used as the sole criteria for
the discoveries of the presence.

the diagnosis of Hepatitis B viral infection.

As with all diagnostic tests, all results must be considered with other clinical information.

# [PERFORMANCE CHARACTERISTICS]

Sensitivity and Specificity

The HBV Combo Rapid Test Cassette (Serum/Plasma) was compared with leading commercial ELWRIA HBsAg, HBsAb, HBsAb, HBsAbsist, the results show that the HBV Combo Rapid Test Cassette (Serum/Plasma) has a high sensitivity and specificity.

Method		EIA	A	Total Results
ii	Results	Positive	Negative	1010111100111
HBsAg Rapid lest	Positive	241	2	243
ssette(Serum/Plasma)	Negative	0	359	359
Total Results		241	361	602

Relative Sensitivity: >99.9% (95%CI\*. 98.8%-100%)
Relative Specificity: 99.4% (95%CI\*. 98.0%-100%)
Accuracy: 99.7% (95%CI\*. 98.8%-100%) \*Confidence Intervals

HBsAb Rapid Test Results Positive 194 **Total Results** 

Cassette(Serum/Plasma)

Relative Sensitivity: 96.5% (95%CI\*: 93.0%-98.6%)
Relative Specificity: 97.8% (95%CI\*: 95.8%-99.0%)
Accuracy: 97.3% (95%CI\*: 95.7%-98.5%) \*ConfidenceIntervals

Relative Sensitivity: 96.3% (95%CI*: 92.1%-98.6%) Relative Specificity: 97.9% (95%CI*: 96.1%-99.1%) Accuracy: 97.5% (95%CI*: 95.9%-98.6%)	Total Result	Casselle(Seldiff lasilla)	HBeAg Kapid Lest	5	Method
y: 96.3% (95%CI*: 92.1%-98.6%) y: 97.9% (95%CI*: 96.1%-99.1%) (95%CI*: 95.9%-98.6%)	its	Negative	Positive	Results	
9.1%)	160	6	154	Positive	
	438	429	9	Negative	25
	598	435	163		I Total Results

Method		m	A	Total Results
	Results	Positive	Negative	10001110001
HBeAb Rapid Test	Positive	146	7	153
Cassette(Serum/Plasma)	Nonetino	4	220	222
	PARTICIONAL		020	400
Total Possilte		150	336	486
i Otal i toodii				

Relative Specificity: 97.9% (95%CI\*: 95.8%-99.2%) Accuracy: 97.7% (95%CI\*: 96.0%-98.9%)

Confidence intervals

Total Results

Relative Sensitivity. 97.8% (95%CI\*: 95.7%-99.1%)

Relative Specificity: 97.7% (95%CI\*: 94.1%-99.4%)

Accuracy: 97.8% (95%CI\*: 96.1%-98.8%) Cassette(Serum/Plasma) **HBcAb Rapid Test** Methoc INCOUNTE Positive 358 **Total Results** 

Confidence Intervals

Within-run precision has been determined by using 15 replicatesof three specimens containing negative, low positive, high positive ofHBsAg, HBsAb, HBeAb, HBcAb. The negative and positive values were correctlyidentified 99% of the time.

Between-run precision has been determined by using the samethree specimens of negative, low positive, high positive of HBsAg, HBsAb, HBsAg, HBsAb, HBsAb, HBsAb, HBsAb, HBsAb, HBsAb hBsab been tested Three different lots of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested the state of the tested the tested the tested the state of the tested the state of the tested the test specimens werecorrectly identified 99% of the time 10 days guisn negative, lowpositive and

Rheumatoid factor HBV Combo Rapid Test Cassette (Serum/Plasma) has (RF), HAV, Syphilis, HIV, H. Pylori, MONO, The results showed no cross-reactivity CMV, Rubella and HAMA,

Interfering Substances

interference from visibly hemolyzed and lipemic specimens. No interference was observed in addition, no interference was observed in specimens containing up to 2,000 mg/dL human serum Albumin. The HBV Combo Rapid Test Cassette (Serum/Plasma)has been tested forpossible mg/dL

BIBLIOGRAPHY

interpretation of serologic tests for hepatitis on the World Wide Web. Clin Perform Qual HealthCare 1997 Apr-Jun 5:61-3

2. ter Bog F., ten Kate F.J., Cuypers H.T., Leentvaar-KuipersA., Oosting J., Wertheim-van Dillen P.M., Honkoop P., Rasch M.C., de Man R.A., vabhaltum J., Chamelueau R.A., Resink H.W., Jones E.A., Relation between laboratory results and histological hepatitis activity in individuals positive for hepatitis B surfaceantigen and antibodies to hepatitis B eantigen, Lancet 1998 June 351:1914-8

Effective date: Number: 145005702 2017-04-13